Skip to content

Platelet Augmentation Using C. Papaya Leaf Extract in Live Donor Liver Transplantation

Efficacy and Safety of Platelet Augmentation Using Carica Papaya Leaf Extract in Live Donor Liver Transplantation Recipients - a Pilot Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05360134
Enrollment
30
Registered
2022-05-04
Start date
2021-01-01
Completion date
2022-12-31
Last updated
2022-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenia

Brief summary

This project is a pilot randomized controlled trial aimed at investigating the potential of Carica Papaya Leaf Extract, available in a marketed pill formulation, in increasing platelet counts in live donor liver transplant recipients. Carica Papaya leaf extract has shown positive results in increasing platelet counts in various medical conditions such as Dengue, Immune thrombocytopenic purpura and chemotherapy induced thrombocytopenia. Thrombocytopenia i.e. low platelet counts are a common occurrence in patients with chronic liver disease undergoing live donor liver transplant. It has been observed in previous studies that live donor liver transplant recipients who have persistent thrombocytopenia have significantly worse outcomes as compared to patients who have higher platelet counts. Positive results in this study lead to further studies in assessing the impact of platelet augmentation in live donor liver transplant recipients.

Interventions

Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7

OTHERPlacebo

Placebo will be given in a similar manner

Sponsors

Institute of Liver and Biliary Sciences, India
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* All consenting adults who are planned to undergo live donor liver transplant with platelet counts less than or equal to 75000/μL preoperatively.

Exclusion criteria

* Patients who do not consent * ALF & ACLF * Pediatric transplant recipients * Allergic to papaya * Preoperative platelet counts \>75,000/ μL * Recent history of DVT

Design outcomes

Primary

MeasureTime frame
POD 7 Platelet Counts7th post-operative day

Secondary

MeasureTime frame
Intra-operative blood loss and transfusion requirementsDay 0
Incidence of Early allograft dysfunctionFirst 7 days following live donor liver transplant
Incidence of prolonged post-operative drainageFirst 14 days following live donor liver transplant
Pre-operative platelet counts1 day prior to surgery

Countries

India

Contacts

Primary ContactAnubhav Harshit Kumar, MCh
anubhav.pawar@gmail.com8860188337

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026